Huntington's Disease

1. Clinical Overview

Summary

Huntington's Disease (HD) is a progressive, fatal, autosomal dominant neurodegenerative disorder caused by an expanded CAG trinucleotide repeat in the HTT gene located on chromosome 4p16.3. [1,2] The disease is characterized by a classic triad of progressive motor dysfunction (chorea being the hallmark), cognitive decline (subcortical dementia), and psychiatric disturbances (depression, apathy, irritability). [3,4]

The mutant huntingtin protein (mHTT) with an elongated polyglutamine tract undergoes toxic aggregation, causing selective degeneration of GABAergic medium spiny neurons in the striatum (caudate nucleus and putamen), resulting in characteristic "boxcar ventricles" on neuroimaging. [5,6] The disease demonstrates genetic anticipation, particularly with paternal transmission, where successive generations experience earlier onset and more severe phenotypes. [7,8]

Symptoms typically manifest between ages 30-50 years, with a mean age of onset around 40 years. [9] Juvenile-onset HD (before age 20), known as the Westphal variant, presents with rigidity and seizures rather than chorea. [10] There is currently no disease-modifying therapy; management focuses on symptomatic relief (tetrabenazine or deutetrabenazine for chorea) and comprehensive multidisciplinary supportive care. [11,12] Death typically occurs 15-20 years after symptom onset, most commonly from aspiration pneumonia or suicide. [13]

Key Facts

• Global Prevalence: 5-10 per 100,000 population worldwide; higher in Western European descent (10-12 per 100,000). [14]
• Inheritance Pattern: Autosomal dominant with 50% offspring risk; virtually 100% penetrance with > 40 CAG repeats.
• Genetic Basis: CAG repeat expansion in exon 1 of HTT gene (chromosome 4p16.3). [1]
• Pathogenic Threshold: ≥36 CAG repeats; full penetrance ≥40 repeats; juvenile HD typically > 60 repeats. [15]
• Anticipation: Disease onset 20-30 years earlier in successive generations, primarily with paternal inheritance. [7,8]
• Neuropathology: Selective striatal GABAergic medium spiny neuron loss; caudate atrophy with lateral ventricle enlargement. [5,6]
• Median Survival: 15-20 years from symptom onset; juvenile HD shows more rapid progression (8-10 years). [13,16]
• Suicide Risk: 5-10-fold higher than general population; accounts for 5-10% of deaths. [17,18]

Clinical Pearls

"Psychiatric Symptoms Precede Chorea": Depression, apathy, and personality changes often appear 5-10 years before motor manifestations. A 35-year-old with unexplained mood disorder and family history warrants consideration of presymptomatic HD. [19,20]

"The Milkmaid's Grip": Patients cannot maintain sustained hand grip; they squeeze and relax rhythmically due to involuntary choreic movements interrupting voluntary muscle contraction.

"Motor Impersistence": Patients cannot sustain tongue protrusion for > 10 seconds ("jack-in-the-box tongue"); this is one of the most sensitive early signs. [21]

"Not All Chorea Is Huntington's": Always consider Wilson's disease (treatable), drug-induced chorea, Sydenham's chorea (post-streptococcal), and paraneoplastic syndromes in the differential diagnosis.

"Suicide Peaks at Diagnosis": The highest suicide risk occurs in the year following diagnosis when insight is preserved but coping mechanisms are undeveloped. [17,18]

---

2. Epidemiology

Incidence and Prevalence

A 2022 systematic review analyzing global data established HD prevalence varies significantly by geographic region and ethnicity. [14]

Age of Onset Distribution

• Juvenile HD (less than 20 years): 5-10% of cases; almost exclusively paternal transmission with > 60 CAG repeats. [10]
• Typical Adult-Onset (30-50 years): 70-75% of cases; peak onset age 35-45 years. [9]
• Late-Onset HD (> 60 years): 20-25% of cases; milder phenotype, slower progression. [22]

Sex Distribution

HD affects males and females equally (1:1 ratio) due to autosomal dominant inheritance. [1] However, male patients more commonly transmit large expansions leading to anticipation and juvenile HD due to instability during spermatogenesis. [7]

Risk Factors

The only established risk factor is inheritance of expanded HTT allele. Environmental modifiers have not been conclusively identified, though DNA repair gene variants (MLH1, MSH3, PMS2) influence age of onset by modulating somatic CAG instability. [23]

---

3. Aetiology and Pathophysiology

Molecular Genetics

The CAG Repeat Expansion

The HTT gene normally contains 10-26 CAG repeats encoding a polyglutamine (polyQ) tract in the huntingtin protein. [1,2] Pathogenic expansion creates four clinically relevant categories:

Genetic Anticipation

HD demonstrates anticipation—the phenomenon of earlier onset and increased severity in successive generations. [7,8] This occurs through:

1. Intergenerational CAG expansion: Repeats increase during gamete formation, particularly in spermatogenesis (10-20 repeat increase possible).
2. Paternal transmission bias: Juvenile HD with massive expansions (> 60 repeats) occurs almost exclusively through paternal inheritance.
3. Somatic mosaicism: CAG repeats continue expanding in somatic tissues throughout life, with highest instability in striatum. [23]

Molecular Pathophysiology

The Toxic Mutant Huntingtin Protein

Normal Huntingtin Function: [24]

• Essential scaffolding protein (348 kDa) involved in axonal transport, particularly brain-derived neurotrophic factor (BDNF) delivery from cortex to striatum
• Critical for embryonic development (HTT knockout mice are embryonic lethal)
• Roles in vesicular trafficking, transcriptional regulation, and synaptic function

Mutant Huntingtin (mHTT) Pathogenesis: [5,25]

The expanded polyglutamine tract confers toxic "gain-of-function" properties:

1. Protein Misfolding and Aggregation

   • Extended polyQ tract promotes β-sheet formation
   • Intranuclear and cytoplasmic inclusion bodies form (visible on histopathology)
   • Sequestration of essential transcription factors (e.g., CREB-binding protein, CBP)

2. Transcriptional Dysregulation

   • Nuclear mHTT interferes with histone acetylation
   • Downregulation of BDNF, leading to striatal neuron trophic support loss [26]
   • Altered expression of hundreds of genes involved in neuronal function

3. Mitochondrial Dysfunction

   • Direct mHTT interaction with mitochondrial membranes
   • Impaired oxidative phosphorylation and ATP production
   • Increased oxidative stress and reactive oxygen species

4. Excitotoxicity

   • Enhanced NMDA receptor sensitivity in striatal neurons
   • Calcium dysregulation leading to neuronal death [27]

5. Impaired Protein Clearance

   • Disrupted autophagy-lysosomal pathway
   • Proteasomal dysfunction preventing mHTT degradation [28]

Selective Striatal Vulnerability

Why does the striatum degenerate first? [5,6]

• GABAergic medium spiny neurons (MSNs) comprise 95% of striatal neurons and are exquisitely vulnerable
• High metabolic demand: MSNs have extensive dendritic arbors requiring substantial energy
• BDNF dependency: Striatum relies on cortical BDNF delivery; mHTT impairs axonal transport [26]
• Excitotoxicity sensitivity: Striatal neurons express high levels of NMDA receptors
• Somatic CAG expansion: Striatum shows highest degree of ongoing CAG expansion, amplifying toxicity [23]

Progression Pattern:

• Early: Dorsal striatum (caudate and putamen) degeneration → chorea
• Intermediate: Globus pallidus, thalamus involvement → worsening motor and cognitive symptoms
• Late: Cortical atrophy (layers III, V, VI) → dementia; cerebellar involvement [29]

Basal Ganglia Circuit Dysfunction

Normal Circuit: [30]

• Direct pathway: Striatum → GPi → Thalamus → Cortex (facilitates movement)
• Indirect pathway: Striatum → GPe → STN → GPi → Thalamus → Cortex (inhibits movement)

In Early HD: [30]

• Preferential loss of indirect pathway MSNs (expressing enkephalin)
• Reduced inhibition of GPe → reduced excitation of GPi → thalamic overactivity
• Result: Excessive cortical activation = CHOREA (hyperkinetic movements)

In Advanced HD:

• Both pathways degenerate
• Loss of direct pathway → reduced thalamic activation
• Result: Rigidity, bradykinesia, akinesia (hypokinetic state)

---

4. Clinical Presentation

HD manifests as a progressive triad of motor, cognitive, and psychiatric symptoms with considerable individual variation in prominence and timing. [3,4]

Motor Symptoms

Chorea (Dance-Like Involuntary Movements)

Characteristics: [21,31]

• Brief, irregular, unpredictable, non-rhythmic involuntary movements
• "Flowing" quality moving from one body part to another
• Initially subtle (fidgetiness, restlessness, "piano-playing" fingers)
• Parakinesia: Incorporation into voluntary movements to mask chorea
• Worsens with stress, improves during sleep
• Affects face (grimacing), trunk (dancing gait), and limbs

Distribution:

• Face: Facial grimacing, brow elevation, tongue protrusion
• Upper limbs: Finger "piano-playing," proximal arm flailing
• Lower limbs: Unsteady gait with lurching, broad-based stance
• Trunk: Axial instability, "dancing" quality to posture

Dystonia

• Sustained muscle contractions causing abnormal postures
• More prominent in juvenile HD and late-stage disease [10]
• Common sites: neck (torticollis), feet (inversion), hands (clenching)

Eye Movement Abnormalities (Highly Specific Signs)

Saccadic Dysfunction: [32]

• Slow saccades: Most sensitive early sign (present before chorea)
• Hypometric saccades: Undershoot targets, requiring multiple corrective movements
• Saccadic initiation difficulty: Head thrusts to move eyes ("gaze apraxia")
• Impaired smooth pursuit: Jerky tracking

Motor Impersistence

Classic bedside signs: [21]

• Tongue protrusion test: Cannot sustain protrusion > 10 seconds ("jack-in-the-box")
• Grip test: Rhythmic squeezing and releasing ("milkmaid's grip")
• Arm extension: Arms drift and fingers wiggle

Gait and Balance Disturbances

• Broad-based, unsteady, "dancing" gait
• Increased fall risk (present in 80% within 10 years of onset)
• Postural instability worsens progressively

Dysphagia and Dysarthria

• Dysarthria: Irregular, hyperkinetic speech; variable volume and rate [33]
• Dysphagia: Progressive swallowing difficulty leading to aspiration risk
  • Present in 80-90% of patients in moderate-advanced stages
  • Leading cause of death (aspiration pneumonia) [34]

Cognitive Symptoms (Subcortical Dementia Pattern)

HD causes progressive cognitive decline distinct from cortical dementias (Alzheimer's). [35,36]

Executive Dysfunction (Most Prominent Feature)

• Impaired planning, organization, sequencing
• Difficulty with set-shifting and mental flexibility
• Poor judgment and decision-making
• Reduced problem-solving abilities

Psychomotor Slowing (Bradyphrenia)

• Slowed processing speed
• Delayed responses to questions
• Difficulty with timed tasks

Attention and Concentration Deficits

• Distractibility
• Impaired sustained attention
• Difficulty with multitasking

Memory Impairment

• Retrieval deficit (not encoding deficit): Recognition better than free recall
• Subcortical pattern: Can learn but has difficulty accessing information
• Contrast to Alzheimer's where new learning is impaired

Preserved Functions (Until Late Stages)

• Language: No aphasia (unlike Alzheimer's)
• Semantic knowledge: Vocabulary and general knowledge retained
• Visuospatial skills: Relatively preserved early

Temporal Pattern: Cognitive symptoms often begin 5-10 years before motor symptoms and progress to dementia in most patients by late stages. [19,20]

Psychiatric Symptoms

Psychiatric manifestations are present in 90% of HD patients and frequently predate motor symptoms. [19,20,37]

Depression (40-50% of patients)

• Often first manifestation (years before chorea)
• May be reactive to diagnosis or intrinsic to neurodegeneration
• Symptoms: Low mood, anhedonia, hopelessness, guilt
• High suicide risk: 5-10-fold increase vs. general population [17,18]

Apathy (30-70% of patients)

• Loss of motivation, interest, and initiative
• Distinct from depression (may coexist)
• Profound impact on function and caregiver burden
• Often precedes other symptoms

Irritability and Aggression (40-50%)

• Emotional lability
• Verbal and physical outbursts
• Difficult for caregivers; major reason for institutionalization

Anxiety Disorders (30-50%)

• Generalized anxiety
• Social anxiety
• Panic attacks

Obsessive-Compulsive Behaviors (10-50%)

• Compulsive rituals
• Perseverative behaviors
• Intrusive thoughts

Psychosis (5-10%)

• Delusions (persecutory most common)
• Hallucinations (rare)
• Typically in advanced disease

Juvenile Huntington's Disease (Westphal Variant)

Definition: Onset before age 20 years (5-10% of HD cases). [10,38]

Genetics:

• Typically > 60 CAG repeats (range 60-100+)
• Almost exclusively paternal transmission (massive expansion in spermatogenesis)

Distinct Clinical Features: [10,38]

Presentation: School performance decline, behavioral problems, seizures, and motor clumsiness are typical first manifestations.

---

5. Differential Diagnosis

Choreiform Movement Disorders

Other Hereditary Ataxias

• Spinocerebellar Ataxias (SCAs): Prominent ataxia; less chorea; CAG repeats in different genes
• Friedreich's Ataxia: Sensory ataxia; areflexia; cardiomyopathy; GAA repeat in FXN gene

Rapidly Progressive Dementias

• Creutzfeldt-Jakob Disease: Myoclonus; rapid progression; MRI DWI/FLAIR hyperintensity; 14-3-3 protein
• Frontotemporal Dementia: Behavioral variant; language variants; no chorea; distinct imaging

---

6. Investigations

Genetic Testing (Definitive Diagnosis)

PCR-Based CAG Repeat Analysis: [39]

• Gold standard diagnostic test
• Measures CAG repeat length in HTT gene
• Sensitivity and specificity: > 99%
• Interpretation:
  • less than 27 repeats: Normal (HD excluded)
  • 27-35 repeats: Intermediate (patient unaffected; expansion risk to offspring)
  • 36-39 repeats: Reduced penetrance (may or may not develop HD)
  • ≥40 repeats: Full penetrance (will develop HD if lifespan sufficient)

Diagnostic Testing (symptomatic individuals): [39]

• Requires informed consent
• Pre-test genetic counseling recommended
• Confirms clinical diagnosis

Predictive Testing (asymptomatic at-risk individuals): [40,41]

Requires strict international protocol:

1. Pre-test counseling (multiple sessions)

   • Explore motivations, psychological readiness, support systems
   • Discuss implications for family, insurance, employment
   • "What will you do if positive?"
   • Suicide risk assessment

2. Cooling-off period (4-12 weeks minimum)

   • Time for reflection
   • Opportunity to withdraw without testing

3. Blood sampling (only if patient persists in request)

4. Result disclosure (in-person only; never by phone/mail)

   • Support person must be present
   • Immediate psychological support available

5. Post-test follow-up

   • Serial psychiatric evaluations
   • Suicide risk monitoring (especially if positive result)

Ethical Considerations: [40,41]

• Testing of minors (less than 18 years) generally prohibited (right to autonomous future decision)
• Exception: Symptomatic children may be tested
• Pre-implantation genetic diagnosis (PGD) available for at-risk couples

Neuroimaging

MRI Brain [42,43]

Characteristic Findings:

• Caudate atrophy: Most sensitive and specific sign

  • Flattening/concavity of caudate head
  • Loss of normal convex bulge into lateral ventricle
  • ""Boxcar ventricles": Parallel lateral ventricle walls due to caudate loss"

• Putaminal atrophy: Often accompanies caudate changes

• Ventricular enlargement: Secondary to striatal volume loss

  • Frontal horns particularly prominent

• Cortical atrophy: Appears in intermediate-late stages

  • Frontal, parietal, and temporal cortex
  • Generalized brain atrophy in advanced disease

Volumetric Measures: [42]

• Caudate volume correlates with CAG repeat length and disease severity
• Used in research trials as outcome measure

Utility in Presymptomatic HD: [44]

• Striatal atrophy detectable 10-15 years before symptom onset
• Progressive in those approaching clinical onset

PET Imaging

• 18F-FDG PET: Striatal hypometabolism (precedes structural atrophy)
• 11C-Raclopride PET: Reduced D2 receptor binding in striatum
• Primarily research tools; not routine clinical practice

SPECT

• Reduced striatal perfusion
• Less commonly used than MRI

Laboratory Investigations

Standard Workup (to exclude mimics):

No specific blood biomarker for HD exists; diagnosis relies on genetic testing.

Clinical Rating Scales

Unified Huntington's Disease Rating Scale (UHDRS): [45]

Four domains:

1. Motor assessment (124 points): Quantifies chorea, dystonia, gait, bradykinesia
2. Cognitive assessment: Verbal fluency, symbol digit, Stroop test
3. Behavioral assessment: Depression, anxiety, irritability, obsessive-compulsive behaviors
4. Functional assessment: Activities of daily living, independence

Total Functional Capacity (TFC): [45]

• Stages disease from 13 (asymptomatic) to 0 (severe disability)
• Based on work capacity, finances, domestic chores, ADLs, care needs

Used in clinical trials and longitudinal monitoring.

---

7. Classification and Staging

Shoulson-Fahn Staging System

Based on Total Functional Capacity (TFC):

Clinical Progression Phases

Presymptomatic (Gene-Positive): [44]

• Genetic mutation present; no clinical signs
• Subtle cognitive and motor changes detectable on research testing 10-15 years before diagnosis
• Striatal atrophy visible on MRI

Prodromal/Early Manifest:

• Subtle motor signs (impersistence, mild chorea)
• Psychiatric symptoms (depression, irritability)
• Mild cognitive changes
• Maintains independence

Moderate Stage:

• Obvious chorea; gait instability; falls
• Cognitive decline affecting work/complex ADLs
• Psychiatric symptoms prominent
• Requires increasing assistance

Advanced Stage:

• Severe motor disability (chorea may decrease; rigidity/dystonia increase)
• Dementia
• Total dependence for ADLs
• Dysphagia; aspiration risk
• Institutionalization often required

---

8. Management

No disease-modifying therapy currently exists. [11,12] Management is symptomatic and supportive with multidisciplinary team approach.

Pharmacological Management

Chorea Treatment

Indications: Only treat if chorea is functionally disabling (interferes with ADLs, safety, or comfort). Mild chorea often does not require treatment.

First-Line: Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors [46,47]

Clinical Pearls:

• Screen for depression/suicidality before initiating VMAT2 inhibitors
• Deutetrabenazine preferred: BID dosing vs TID; improved tolerability; lower depression risk [48]
• Titrate slowly to minimize side effects
• Monitor for development of parkinsonism (reduce dose if occurs)

Second-Line: Antipsychotics (Dopamine Receptor Antagonists) [49]

Caution: Risk of tardive dyskinesia, parkinsonism, sedation, metabolic syndrome.

Psychiatric Symptom Management

Depression and Anxiety: [50]

• SSRIs: First-line (citalopram 10-40 mg, sertraline 50-200 mg, escitalopram 10-20 mg)
• SNRIs: Venlafaxine, duloxetine (if SSRIs ineffective)
• Mirtazapine: Useful if insomnia/weight loss coexist
• Close monitoring for suicidality, especially after diagnosis

Irritability and Aggression: [50]

• SSRIs: First-line
• Mood stabilizers: Valproate 500-1500 mg/day, lamotrigine 100-200 mg/day
• Atypical antipsychotics: Olanzapine, quetiapine (if severe)

Psychosis: [50]

• Atypical antipsychotics: Olanzapine 5-20 mg, quetiapine 100-400 mg, risperidone 1-4 mg
• Avoid typical antipsychotics (higher EPS risk, though may be used cautiously)

Apathy:

• No consistently effective pharmacological treatment
• Behavioral activation strategies
• Trials of dopaminergic agents (limited evidence)

Cognitive Symptoms

• No FDA-approved cognitive therapies
• Cholinesterase inhibitors (donepezil, rivastigmine): Minimal evidence; not routinely recommended
• Memantine: No proven benefit in HD

Juvenile HD Specific Treatments [10,38]

• Rigidity/Dystonia: Baclofen, trihexyphenidyl (anticholinergics), benzodiazepines
• Seizures: Standard anticonvulsants (levodopa, valproate, levetiracetam)
• Avoid dopamine-depleting agents if already rigid/bradykinetic

Non-Pharmacological Management

Multidisciplinary Team Approach [51]

Neurology: Overall coordination, symptom management, disease monitoring

Physiotherapy: [52]

• Gait training and balance exercises (reduce fall risk)
• Strength and flexibility maintenance
• Exercise programs: Evidence for improved motor function, mood, cognition
• Fall prevention strategies; home safety assessment

Occupational Therapy:

• ADL adaptations and assistive devices
• Cognitive rehabilitation strategies
• Home modifications (grab bars, shower chairs)

Speech and Language Therapy (SALT): [34,53]

• Dysarthria management: Speech exercises, communication aids
• Dysphagia assessment and management:
  • Videofluoroscopy (modified barium swallow) to assess aspiration risk
  • Texture modification (thickened liquids, pureed diet)
  • Postural adjustments during eating
  • Consideration of PEG tube in advanced dysphagia (ethical discussions required)

Dietetics: [54]

• HD patients are hypercatabolic: Require 3000-5000 kcal/day to maintain weight
• High-calorie, high-protein diet
• Nutritional supplements
• Weight monitoring
• Address swallowing difficulties with texture modification

Psychology/Psychiatry:

• Psychological support for patient and family
• Suicide risk assessment and monitoring
• Treatment of psychiatric comorbidities
• Advance care planning discussions

Social Work:

• Financial planning; disability benefits
• Caregiver support and respite care
• Nursing home placement when appropriate
• Support groups (Huntington's Disease Society of America, European HD Network)

Genetic Counseling: [40,41]

• Family pedigree assessment
• Reproductive options (PGD, prenatal testing, adoption)
• Predictive testing protocol for at-risk relatives
• Ethical considerations

Exercise and Rehabilitation [52]

• Aerobic exercise: Improves motor function, mood, and possibly cognition
• Resistance training: Maintains strength and functional capacity
• Balance training: Reduces fall risk
• Evidence suggests exercise may slow functional decline

Surgical/Interventional Therapies

Deep Brain Stimulation (DBS) [55,56]

• Target: Globus pallidus internus (GPi)
• Indication: Severe, medically refractory chorea significantly impairing quality of life
• Outcomes:
  • Moderate reduction in chorea severity (30-50% improvement)
  • Does NOT improve cognition, psychiatric symptoms, or progression
  • May worsen cognitive function in some patients
• Patient Selection: Preserved cognition essential; primarily for motor symptoms
• Limited use; not standard of care

PEG Tube Feeding

• Considered in advanced dysphagia with recurrent aspiration pneumonia or severe weight loss
• Ethical considerations: Quality of life vs prolongation of survival; advance directive discussions critical
• Not shown to prolong survival in HD but may reduce aspiration episodes

Emerging and Experimental Therapies

Huntingtin-Lowering Strategies [57,58]

Antisense Oligonucleotides (ASOs):

• Tominersen (IONIS-HTTRx, RG6042): Intrathecal ASO targeting HTT mRNA

  • "Phase 3 GENERATION-HD1 trial: Halted in 2021 due to lack of efficacy and potential worsening [58]"
  • Dose-dependent HTT lowering achieved but no clinical benefit
  • Higher doses associated with worse outcomes
  • Future trials exploring lower doses or allele-specific targeting

• WVE-003 (Wave Life Sciences): Allele-selective ASO (targets mutant HTT preferentially)

  • Early-phase trials ongoing

RNA Interference (RNAi):

• Gene silencing via siRNA delivered intrathecally or via AAV vectors
• Preclinical and early clinical development

Gene Editing:

• CRISPR/Cas9 approaches to inactivate mutant HTT allele
• Zinc finger nucleases
• Preclinical research; not yet in human trials

Small Molecules:

• Compounds targeting mHTT aggregation, mitochondrial function, or DNA repair
• Multiple agents in early-phase trials

Current Status: No huntingtin-lowering therapy has demonstrated clinical efficacy. Research ongoing but significant hurdles remain.

Other Investigational Therapies

• Pridopidine: Sigma-1 receptor agonist; neuroprotective effects in animal models; Phase 3 trial (PROOF-HD) showed trends but did not meet primary endpoint [59]
• Laquinimod: Immunomodulator; Phase 2 trial (LEGATO-HD) showed some slowing of brain atrophy but no functional benefit [60]
• Creatine, Coenzyme Q10: Mitochondrial support; large trials negative

---

9. Complications

Medical Complications

Psychiatric Complications

Social and Legal Complications

• Loss of Employment: Typically within 5-10 years of onset
• Loss of Driving Ability: Motor and cognitive impairment; assess fitness to drive regularly
• Financial Difficulties: Loss of income; high care costs; financial planning essential
• Family Conflict: Genetic testing decisions; caregiver stress; advance care planning disputes
• Institutionalization: Required in majority by late stages

---

10. Prognosis

Natural History

• Diagnosis to Death: Median survival 15-20 years (range 10-30 years). [13,16]
• Age-Related Variation:
  • "Juvenile-onset HD: More rapid progression (8-10 years survival)"
  • "Typical adult-onset (30-50 years): 15-20 years survival"
  • "Late-onset (> 60 years): Slower progression (may survive 20-25 years)"

Causes of Death [13]

1. Aspiration Pneumonia: 40-50% (leading cause)
2. Suicide: 5-10%
3. Other Infections: Urinary tract infections, sepsis
4. Cardiovascular Disease: Similar rates to general population
5. Cachexia/Inanition: End-stage malnutrition

Prognostic Factors

Poorer Prognosis (Faster Decline):

• Higher CAG repeat count: Each additional CAG repeat reduces onset age by ~2-3 years; correlates with progression rate [15]
• Earlier age of onset: Juvenile HD progresses most rapidly
• Rapid motor progression in first years: Predicts overall disease course
• Significant cognitive impairment at diagnosis: Faster functional decline
• Psychiatric comorbidity severity: Impacts quality of life and suicide risk

Modifiers of Progression: [23]

• DNA mismatch repair gene variants (MLH1, MSH3, PMS2) influence age of onset
• No proven environmental modifiers

Functional Decline

• Years 1-5: Mild motor symptoms; maintain employment and independence; psychiatric symptoms may dominate
• Years 5-10: Progressive chorea; cognitive decline; loss of employment; increasing ADL dependence
• Years 10-15: Severe motor disability; dementia; significant dysphagia; high care needs
• Years 15-20: Bedbound; akinetic-rigid; mute; total dependence; end-of-life care

Quality of Life

• Progressively declining quality of life due to motor, cognitive, and psychiatric symptoms
• Loss of independence profoundly impacts dignity and self-worth
• Caregiver quality of life also severely affected
• Advance care planning essential to honor patient wishes

---

11. Prevention and Genetic Counseling

Primary Prevention

• Reproductive Options for At-Risk Individuals: [40,41]

  1. Pre-implantation Genetic Diagnosis (PGD):

     • IVF with embryo biopsy and CAG repeat analysis
     • Only unaffected embryos implanted
     • "Exclusion testing": Can avoid affected offspring without revealing parent's genetic status (test for grandparent's haplotype)

  2. Prenatal Testing (CVS at 11-13 weeks; amniocentesis at 15-18 weeks):

     • Fetal CAG repeat analysis
     • Raises ethical issues regarding termination of pregnancy
     • Requires pre-test counseling on intended actions if positive

  3. Adoption: Avoids genetic transmission

  4. Use of Donor Gametes: Sperm/egg donation from unaffected individuals

Secondary Prevention

• Predictive Testing: Identifies asymptomatic gene carriers who can make informed life decisions (reproduction, career, finances)
• Early Intervention Trials: Research protocols enrolling presymptomatic gene carriers to test neuroprotective agents (none proven effective to date)

Tertiary Prevention

• Symptomatic management to reduce complications (see Management section)
• Palliative care to optimize quality of life

Genetic Counseling Principles [40,41]

• Non-directive: Counselor provides information; patient makes autonomous decisions
• Confidentiality: Genetic information highly sensitive; insurance/employment discrimination concerns
• Family Implications: One person's test affects at-risk relatives (shared genetic information)
• Psychological Impact: Testing can cause severe distress regardless of result
• Right Not to Know: Respect patient's decision to decline predictive testing

---

12. Key Guidelines and Evidence

Major Clinical Guidelines

1. American Academy of Neurology (AAN): Quality Standards Subcommittee guidelines on genetic testing and counseling (2017) [40]

2. European Huntington's Disease Network (EHDN): Recommendations on clinical management and research standards

3. Huntington Study Group (HSG): Expert consensus on symptomatic management of motor and psychiatric symptoms (2018) [50]

4. International Parkinson and Movement Disorder Society: Evidence-based review of HD treatments (2018) [49]

5. World Federation of Neurology Research Group on Huntington's Chorea: Guidelines on predictive testing protocols (1994, updated 2013) [41]

Landmark Studies

• GENERATION-HD1 (Tominersen Trial): Phase 3 trial of huntingtin-lowering ASO; halted 2021 due to lack of efficacy and potential harm [58]

• ARC-HD and FIRST-HD (Deutetrabenazine Trials): Demonstrated efficacy in reducing chorea with better tolerability than tetrabenazine [47,48]

• PREDICT-HD: Longitudinal study of presymptomatic gene carriers identifying early biomarkers and predictors of onset [44]

• TRACK-HD: Longitudinal imaging study establishing progressive brain atrophy years before symptom onset [42]

• GeM-HD (Genetic Modifiers of Huntington's Disease): Identified DNA repair genes as modifiers of age of onset [23]

---

13. Clinical Vignettes and Exam Focus

Case 1: Classic Adult-Onset Presentation

Scenario: A 42-year-old man presents with 2-year history of progressive "fidgetiness" and clumsiness. His wife reports personality change with irritability and apathy. His father died in a psychiatric hospital at age 55 with "movement problems." Examination shows subtle chorea in fingers, motor impersistence (cannot sustain tongue protrusion), and slow saccades.

Diagnosis: Huntington's disease

Next Steps:

• Detailed family history (confirm father's diagnosis if possible)
• Pre-test genetic counseling
• Genetic testing: PCR for HTT CAG repeat count
• MRI brain (expect caudate atrophy/"boxcar ventricles")
• Psychiatric evaluation (suicide risk assessment)
• Multidisciplinary team referral

Key Teaching Points:

• Psychiatric and subtle motor symptoms often precede overt chorea by years
• Positive family history highly suggestive but ~10% are new mutations or have incomplete family history
• Motor impersistence and saccadic dysfunction are early, sensitive signs

---

Case 2: Juvenile Huntington's Disease (Westphal Variant)

Scenario: A 16-year-old boy with declining school performance over 2 years now develops rigidity, bradykinesia, and tonic-clonic seizures. His gait is slow and stiff. His father was diagnosed with Huntington's disease at age 40. Examination shows masked facies, rigidity, bradykinesia, and dystonic posturing. No chorea.

Diagnosis: Juvenile Huntington's disease (Westphal variant)

Genetic Testing: Expected to show > 60 CAG repeats with paternal inheritance.

Management:

• Anticonvulsants for seizures
• Avoid dopamine-depleting agents (already rigid/bradykinetic)
• Baclofen or benzodiazepines for rigidity
• Multidisciplinary support (educational, psychological)
• Family counseling (father may have other at-risk children)

Key Teaching Points:

• Juvenile HD presents with rigidity/bradykinesia (Parkinsonian), NOT chorea
• Seizures common in juvenile HD (30-50%), rare in adult-onset HD
• Almost exclusively paternal transmission with massive CAG expansion (> 60 repeats)
• Rapid progression with poor prognosis (8-10 years)

---

Case 3: Ethical Dilemma in Predictive Testing

Scenario: A healthy 25-year-old woman whose father has Huntington's disease requests predictive genetic testing. She is engaged to be married and wants to know her status before having children. She states, "I need to know now. Just do the blood test."

Appropriate Response:

• Do NOT perform immediate testing
• Refer to genetic counseling service
• Follow international predictive testing protocol:
  1. Pre-test counseling sessions (motivations, psychological readiness, implications)
  2. Cooling-off period (minimum 4-12 weeks for reflection)
  3. Opportunity to withdraw
  4. Blood test only if patient persists
  5. Result disclosure in-person with support person present
  6. Post-test psychological follow-up

Discussion Points:

• She has 50% risk of inheriting the mutation
• Positive result: Will develop HD; no cure; life-altering information
• Implications for insurance, employment, relationships, children
• Suicide risk (especially post-positive result)
• Reproductive options: PGD (IVF with embryo testing), prenatal testing, adoption, donor gametes
• Right to decline testing and maintain uncertainty ("right not to know")

Ethical Principle: Respect for autonomy while ensuring informed decision-making and psychological protection.

---

Common Exam Questions (MRCP, FRACP, Neurology Boards)

Question 1: What is the mechanism of anticipation in Huntington's disease?

Model Answer: "Anticipation in Huntington's disease refers to the phenomenon of earlier onset and increased severity in successive generations. This occurs due to CAG trinucleotide repeat expansion during gamete formation, particularly spermatogenesis, leading to larger repeat numbers in offspring compared to parents. The instability is greater in male germline transmission, explaining why juvenile HD with very large expansions (> 60 repeats) almost exclusively occurs with paternal inheritance. Each additional CAG repeat correlates with approximately 2-3 years earlier disease onset."

---

Question 2: A patient with confirmed Huntington's disease develops functionally disabling chorea. What is the mechanism of action of tetrabenazine, and what is the major side effect of concern?

Model Answer: "Tetrabenazine is a vesicular monoamine transporter type 2 (VMAT2) inhibitor. It blocks the packaging of monoamines (dopamine, serotonin, norepinephrine) into presynaptic vesicles, leading to depletion of presynaptic dopamine stores and reduced dopaminergic neurotransmission. This suppresses chorea. The major side effect of concern is depression and suicidality, which carries a BLACK BOX WARNING. Huntington's disease patients already have elevated suicide risk (5-10-fold higher than general population), so careful screening and monitoring is essential. Deutetrabenazine, a deuterated form, has a better safety profile with lower depression risk while maintaining efficacy."

---

Question 3: Describe the clinical and genetic features that distinguish juvenile Huntington's disease from adult-onset Huntington's disease.

Model Answer:

---

Question 4: What are the characteristic MRI findings in Huntington's disease and what is their pathophysiological basis?

Model Answer: "The characteristic MRI finding in Huntington's disease is caudate atrophy, manifesting as flattening or concavity of the caudate head (normally convex bulge into lateral ventricle). This leads to enlarged frontal horns of the lateral ventricles with parallel walls, termed 'boxcar ventricles'. Putaminal atrophy also occurs. The pathophysiological basis is selective degeneration of GABAergic medium spiny neurons in the striatum (caudate and putamen) due to toxic mutant huntingtin protein aggregation. In advanced disease, cortical atrophy (frontal, parietal, temporal) develops, along with generalized brain volume loss."

---

Question 5: Why does the striatum degenerate selectively in Huntington's disease?

Model Answer: "Several factors contribute to selective striatal vulnerability:

1. BDNF dependency: Striatal neurons rely heavily on brain-derived neurotrophic factor (BDNF) delivered via axonal transport from cortex. Mutant huntingtin impairs BDNF transport and production, selectively depriving striatal neurons of critical trophic support.

2. High metabolic demand: GABAergic medium spiny neurons (95% of striatum) have extensive dendritic arbors requiring substantial energy; metabolic dysfunction from mutant huntingtin causes particular vulnerability.

3. Excitotoxicity: Striatal neurons express high levels of NMDA receptors; mutant huntingtin enhances NMDA receptor sensitivity, leading to calcium overload and excitotoxic cell death.

4. Somatic CAG instability: The striatum shows the highest degree of ongoing CAG repeat expansion in somatic cells, amplifying mutant huntingtin toxicity over time.

These factors converge to cause preferential striatal degeneration, though other brain regions are eventually affected."

---

14. Advanced Topics

The Huntingtin Protein: Structure and Function [24,25]

Normal Huntingtin:

• Large scaffolding protein (3144 amino acids; 348 kDa)
• Widely expressed in CNS and periphery; highest in brain and testes
• Contains multiple HEAT (Huntingtin, Elongation factor 3, PR65/A, TOR) repeats forming α-helical solenoid structure
• Functions:
  • Axonal transport (kinesin and dynein motor protein interactions)
  • BDNF vesicular transport from cortex to striatum
  • Synaptic vesicle trafficking
  • Transcriptional regulation (scaffolding for transcription factors)
  • Anti-apoptotic functions (sequesters pro-apoptotic proteins)
  • Essential for development (HTT knockout is embryonic lethal in mice)

Mutant Huntingtin (mHTT):

• Expanded polyglutamine (polyQ) tract at N-terminus
• Conformational change → β-sheet formation → aggregation
• Proteolytic cleavage generates toxic N-terminal fragments containing polyQ
• Intranuclear and cytoplasmic inclusion bodies (aggregates)
• Gain-of-toxic-function dominates pathogenesis (not loss of normal function)

Somatic Instability and Disease Progression [23]

• CAG repeats are unstable in somatic cells, expanding throughout life
• Expansion occurs in an age-dependent and tissue-specific manner
• Striatum shows greatest instability, potentially explaining selective vulnerability
• DNA mismatch repair (MMR) genes modulate somatic expansion:
  • Variants in MLH1, MSH3, PMS2 are genetic modifiers of HD onset age
  • MMR proteins normally repair DNA replication errors
  • In HD, paradoxically contribute to CAG expansion through aberrant repair processes
• Therapeutic strategy: Inhibit somatic expansion to slow disease (in preclinical development)

Transcriptional Dysregulation [26]

Mutant huntingtin disrupts gene expression programs critical for neuronal survival:

• Histone acetylation defects: Sequestration of CBP (CREB-binding protein) and p300 histone acetyltransferases → transcriptional repression
• BDNF downregulation: Reduced cortical BDNF production and impaired transport → striatal neuron deprivation
• PGC-1α suppression: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (master regulator of mitochondrial biogenesis) is downregulated → mitochondrial dysfunction
• SP1 sequestration: Specificity protein 1 trapped in aggregates → altered downstream gene expression
• RE1-silencing transcription factor (REST) dysregulation: Abnormal nuclear localization → repression of neuronal genes

The Tominersen Failure: Lessons Learned [58]

Background: Tominersen (IONIS-HTTRx, RG6042) was the first huntingtin-lowering therapy to reach Phase 3 trials.

Mechanism: Antisense oligonucleotide (ASO) delivered intrathecally; binds HTT mRNA → RNase H-mediated degradation → reduced huntingtin protein production (both normal and mutant).

GENERATION-HD1 Trial (Phase 3):

• Enrolled early manifest HD patients
• Intrathecal dosing every 2 months
• Primary endpoint: Composite Unified HD Rating Scale (cUHDRS)

Results (March 2021):

• Trial halted for futility and potential harm
• Dose-dependent HTT lowering confirmed (up to 50% reduction in CSF)
• No clinical benefit on primary or secondary outcomes
• Higher doses associated with worse outcomes (faster decline)
• Unexpected finding: CSF neurofilament light (NfL, neurodegeneration marker) increased with treatment

Lessons:

1. HTT lowering alone may be insufficient (timing? too late in disease course?)
2. Normal huntingtin has critical functions: Non-selective lowering may cause harm
3. Allele-selective approaches (targeting mutant HTT only) may be necessary
4. Earlier intervention in presymptomatic stage may be required
5. Biomarkers (NfL) essential for monitoring safety

Future Directions:

• Allele-selective ASOs (WVE-003)
• RNAi approaches
• Gene editing (CRISPR/Cas9)
• Combination therapies (HTT lowering + neuroprotection)
• Presymptomatic trials

---

15. Palliative and End-of-Life Care

Advance Care Planning [62]

Timing: Discussions should begin early in disease course when patient has decision-making capacity.

Key Topics:

1. Goals of Care: Quality of life vs prolongation of life
2. Resuscitation Status: DNR/DNI preferences
3. Artificial Nutrition: PEG tube feeding decisions
4. Mechanical Ventilation: Preferences in respiratory failure
5. Place of Death: Home vs hospital vs hospice
6. Organ Donation: Considerations (brain tissue valuable for research)

Legal Documents:

• Advance Directive (Living Will)
• Durable Power of Attorney for Healthcare (Healthcare Proxy)
• POLST (Physician Orders for Life-Sustaining Treatment)

Late-Stage Care Challenges [62]

Total Dependency:

• Bedbound; requires turning every 2 hours (pressure ulcer prevention)
• Incontinent (indwelling catheter or scheduled toileting)
• Non-verbal (communication via eye gaze or yes/no signals)
• Dysphagia (PEG feeding or comfort feeding only)

Symptom Management:

• Pain: Opioids (morphine, fentanyl patch); non-verbal pain assessment scales
• Dystonia: Botulinum toxin injections; baclofen; benzodiazepines
• Secretions: Glycopyrrolate, hyoscine (scopolamine)
• Terminal Agitation: Haloperidol, midazolam, levomepromazine
• Dyspnea: Opioids, oxygen, fans

Ethical Issues:

• PEG tube feeding: Prolongs life but may not improve quality; patient/family values central
• Antibiotics for pneumonia: Treat vs comfort measures only
• Hospital transfer vs hospice care
• Balancing caregiver burden with patient wishes

Caregiver Support [51]

• Respite Care: Essential to prevent burnout (day programs, short-term institutional placement)
• Support Groups: Huntington's Disease Society of America (HDSA), European HD Network (EHDN)
• Counseling: Individual and family therapy
• Financial Assistance: Disability benefits, long-term care insurance
• Education: Anticipatory guidance on disease progression

Caregiver Burden: Caring for HD patients is physically and emotionally exhausting; caregiver depression and burnout rates are extremely high.

---

16. Special Populations

Women and Pregnancy

Pre-Pregnancy Counseling:

• 50% risk of transmitting mutation to offspring
• Reproductive options: PGD, prenatal testing, adoption, donor eggs/sperm
• Predictive testing before pregnancy (if desired)

Pregnancy in Affected Women:

• HD does not typically affect fertility or pregnancy outcomes
• Chorea may worsen or improve during pregnancy (unpredictable)
• Medications: Tetrabenazine/deutetrabenazine generally avoided (limited safety data); SSRIs relatively safe
• Labor and delivery: Chorea may intensify with pain/stress; epidural analgesia helpful

Postnatal:

• Parenting capacity assessment (if symptomatic)
• Child welfare considerations (genetic risk to child; parent's progressive disability)

Elderly Patients (Late-Onset HD) [22]

• Onset > 60 years (20-25% of cases)
• Typically lower CAG repeats (36-45 range)
• Milder phenotype: Less severe chorea; slower progression
• Diagnostic challenge: Overlapping features with age-related conditions (Parkinson's, Alzheimer's)
• Comorbidities complicate management (polypharmacy, cardiovascular disease)

Pediatric Considerations (Juvenile HD) [10,38]

• Educational impact: School failure often first sign
• Behavioral problems may mimic ADHD, conduct disorder
• Seizure management: Standard anticonvulsants
• Psychological impact on child and siblings
• Ethical prohibition on predictive testing of asymptomatic minors (right to autonomous future decision)

---

17. Differential Diagnosis: Detailed Approach

Approach to Chorea [63]

Step 1: Confirm Chorea

• Brief, irregular, unpredictable, flowing movements
• Distinguish from: tremor (rhythmic), myoclonus (shock-like), tics (suppressible, stereotyped), athetosis (slow, writhing)

Step 2: Age of Onset

Children/Adolescents:

• Sydenham's chorea: Post-streptococcal; self-limited; rheumatic fever
• Benign hereditary chorea: Childhood onset; non-progressive; TITF1 mutation
• Wilson's disease: Treatable; Kayser-Fleischer rings; low ceruloplasmin
• Ataxia-telangiectasia: Ataxia, telangiectasias, immunodeficiency
• Drug-induced: Stimulants (methylphenidate), anticonvulsants

Adults (20-50 years):

• Huntington's disease: Most common genetic cause; family history; CAG repeat
• Wilson's disease: Must exclude (treatable); onset up to age 40
• Neuroacanthocytosis: Acanthocytes; elevated CK; self-mutilation (lip/tongue biting)
• SLE chorea: Young women; antiphospholipid antibodies; other SLE features
• Drug-induced: Levodopa, dopamine agonists, anticonvulsants, OCP, antipsychotics (tardive dyskinesia)
• Hyperthyroidism: Chorea rare manifestation
• Polycythemia vera: Rare cause
• Paraneoplastic: Anti-CRMP5, anti-Hu antibodies; lung, ovarian cancer

Elderly (> 60 years):

• Tardive dyskinesia: Chronic antipsychotic use; oro-buccal-lingual predominance
• Vascular chorea: Stroke involving basal ganglia (caudate, putamen)
• Senile chorea: Diagnosis of exclusion; age-related basal ganglia changes
• Late-onset HD: Consider even in elderly without family history

Step 3: Investigations to Differentiate

---

18. Research Horizons and Future Directions

Biomarkers for Presymptomatic HD [44]

Goal: Identify objective measures of disease progression in presymptomatic individuals for early intervention trials.

Promising Biomarkers:

1. Neuroimaging:

   • Striatal volume (caudate, putamen): Progressive atrophy 10-15 years before symptom onset
   • White matter microstructure (DTI): Early changes in connectivity
   • Functional MRI: Altered brain activation patterns during cognitive tasks

2. Fluid Biomarkers:

   • Neurofilament light (NfL) in CSF and plasma: Elevated in presymptomatic HD; correlates with disease burden
   • Mutant huntingtin protein in CSF: Directly measures pathogenic protein; target engagement biomarker for HTT-lowering therapies

3. Cognitive Testing:

   • Subtle deficits detectable 10+ years before diagnosis (executive function, processing speed)

4. Motor Testing:

   • Quantitative motor assessments detect subclinical abnormalities (force variability, fine motor control)

Clinical Utility: Enable presymptomatic trials; predict time to onset; monitor therapeutic response.

Gene Therapy Approaches [64]

1. Allele-Selective Silencing:

   • Target mutant HTT allele specifically (spare normal huntingtin)
   • Exploit SNP differences between alleles
   • ASOs, RNAi, microRNA-based approaches

2. CRISPR/Cas9 Gene Editing:

   • Inactivate mutant HTT gene permanently
   • Challenges: Delivery to brain; off-target effects; irreversibility
   • AAV vectors for delivery

3. Zinc Finger Nucleases/TALENs:

   • Alternative gene editing platforms

Challenges: CNS delivery; safety (off-target effects); permanence (irreversible interventions); regulatory approval.

Modulating Somatic Instability [23]

• Rationale: Somatic CAG expansion correlates with disease progression
• Approach: Inhibit DNA mismatch repair (MMR) pathways driving expansion
• Targets: MSH3, MLH1, PMS2 proteins
• Potential: Slow expansion → delay onset/progression
• Preclinical studies promising; early-phase trials planned

Neuroprotective Strategies

• Mitochondrial support: Creatine, CoQ10 (trials negative); triheptanoin (ongoing trials)
• Anti-inflammatory: Laquinimod (some brain atrophy reduction but no functional benefit) [60]
• Sigma-1 receptor agonists: Pridopidine (trends in Phase 3 but missed endpoints) [59]
• Autophagy enhancers: Clear mHTT aggregates
• BDNF enhancement: Restore trophic support to striatum

Combination Therapies

• Future likely requires multi-pronged approach:
  • HTT lowering (reduce toxic protein)
  • Neuroprotection (support neuronal survival)
  • Somatic instability modulation (slow CAG expansion)
  • Symptomatic management (optimize quality of life)

---

19. Patient and Family Resources

Patient Education (Layperson Explanation)

What is Huntington's Disease?

Huntington's disease is an inherited brain disorder that affects movement, thinking, and emotions. It is caused by a mistake in a single gene (HTT) that is passed down in families. The gene has a section that repeats too many times (like a stutter), producing an abnormal protein that slowly damages brain cells, particularly in an area called the striatum.

What are the symptoms?

The disease causes three main types of problems:

1. Movement problems: Uncontrollable jerky movements (chorea), clumsiness, difficulty walking
2. Thinking problems: Difficulty concentrating, planning, making decisions; memory issues; eventually dementia
3. Emotional/behavioral problems: Depression, mood swings, irritability; sometimes personality changes

Symptoms usually start in the 30s or 40s but can begin earlier or later. The disease slowly gets worse over 15-20 years.

How is it inherited?

HD is autosomal dominant, meaning:

• If one parent has HD, each child has a 50% chance of inheriting the gene and will develop HD if they live long enough
• It affects males and females equally
• You only need one copy of the abnormal gene (from one parent) to get the disease

Is there a test?

Yes, a simple blood test can detect the gene mutation with > 99% accuracy. Testing involves genetic counseling to understand the implications. Healthy people at risk can choose to be tested (predictive testing) but this requires careful counseling and psychological support.

Is there a cure?

Currently, there is no cure and no treatment that slows the disease. However:

• Medications can help control the involuntary movements (chorea)
• Antidepressants and other psychiatric medications help with mood and behavioral problems
• Physical therapy, speech therapy, and occupational therapy improve quality of life
• Research is actively working on treatments to slow or stop the disease

What can families do?

• Connect with support groups (Huntington's Disease Society of America, European HD Network)
• Plan ahead: financial planning, advance directives, care needs
• Genetic counseling for family members
• Consider reproductive options (genetic testing of embryos, prenatal testing, adoption)
• Participate in research studies to help find treatments

Support Organizations

United States:

• Huntington's Disease Society of America (HDSA): www.hdsa.org
  • Support groups, educational materials, care coordination
  • HDSA Centers of Excellence (specialized clinics)
  • Youth programs (for children of affected parents)

United Kingdom:

• Huntington's Disease Association (HDA): www.hda.org.uk

Europe:

• European Huntington's Disease Network (EHDN): www.ehdn.org

Australia:

• Huntington's NSW & ACT: www.huntingtonsnsw.org.au
• Huntington's Victoria: www.huntingtonsvic.org.au

International:

• International Huntington Association (IHA): www.huntington-assoc.com

Research Participation:

• Enroll-HD: Global observational study; www.enroll-hd.org
• Clinical trial registries: www.clinicaltrials.gov (search "Huntington's disease")

---

20. Summary: High-Yield Facts for Examinations

Genetics

• Autosomal dominant CAG trinucleotide repeat expansion in HTT gene (chromosome 4p16.3)
• Anticipation: Earlier onset in successive generations (paternal transmission → juvenile HD)
• Pathogenic threshold: ≥36 repeats; full penetrance ≥40; juvenile HD > 60
• Mechanism: Expanded polyglutamine tract → toxic protein aggregation → neuronal death

Pathology

• Selective striatal GABAergic medium spiny neuron degeneration
• Caudate and putamen atrophy → "boxcar ventricles" on MRI
• Loss of indirect pathway (early) → thalamic disinhibition → chorea
• Loss of both pathways (late) → rigidity, akinesia

Clinical Triad

1. Motor: Chorea, dystonia, motor impersistence, saccadic dysfunction, dysphagia
2. Cognitive: Subcortical dementia (executive dysfunction, psychomotor slowing)
3. Psychiatric: Depression (40-50%), apathy, irritability, suicide risk (5-10× baseline)

Juvenile HD (Westphal Variant)

• Onset less than 20 years; > 60 CAG repeats; paternal transmission
• Rigidity/bradykinesia (NOT chorea), seizures (30-50%), rapid progression

Diagnosis

• Genetic testing: PCR for CAG repeat count (> 99% sensitivity/specificity)
• MRI: Caudate atrophy, "boxcar ventricles"
• Exclude Wilson's disease (treatable; ceruloplasmin, slit-lamp)

Management

• No disease-modifying therapy
• Chorea: Tetrabenazine or deutetrabenazine (VMAT2 inhibitors; BLACK BOX WARNING for depression/suicide)
• Psychiatric: SSRIs, mood stabilizers, atypical antipsychotics
• Multidisciplinary: PT, OT, SALT (dysphagia), dietician (high-calorie diet 3000-5000 kcal/day)

Prognosis

• 15-20 years survival from onset (juvenile HD: 8-10 years)
• Death: Aspiration pneumonia (40-50%), suicide (5-10%)

Predictive Testing Ethics

• Requires strict protocol: Pre-test counseling, cooling-off period, in-person result disclosure, post-test support
• Minors (less than 18) generally NOT tested (right to autonomous future decision)

Emerging Therapies

• Huntingtin-lowering: Tominersen (ASO) failed Phase 3 (2021); research ongoing
• Gene therapy, allele-selective silencing, somatic instability modulation: Experimental

---

21. References

1. Bates GP, et al. Huntington disease. Nat Rev Dis Primers. 2015;1:15005. doi:10.1038/nrdp.2015.5

2. Ross CA, Tabrizi SJ. Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83-98. doi:10.1016/S1474-4422(10)70245-3

3. Stoker TB, et al. Huntington's disease: diagnosis and management. Pract Neurol. 2022;22(1):32-41. doi:10.1136/practneurol-2021-003074

4. Ghosh R, et al. Clinical Features of Huntington's Disease. Adv Exp Med Biol. 2018;1049:1-28. doi:10.1007/978-3-319-71779-1_1

5. Reiner A, et al. Disrupted striatal neuron inputs and outputs in Huntington's disease. CNS Neurosci Ther. 2018;24(4):250-280. doi:10.1111/cns.12844

6. Castro E, et al. Predictive Modeling of Huntington's Disease Unfolds Thalamic and Caudate Atrophy. Mov Disord. 2022;37(11):2358-2364. doi:10.1002/mds.29219

7. Sumaiya T, et al. Presentation Modes, Anticipation, and Penetrance: A Case Series of Huntington's Disease. Cureus. 2025;17(1):e94101. doi:10.7759/cureus.94101

8. Paulson H, et al. Repeat expansion diseases. Handb Clin Neurol. 2018;147:105-123. doi:10.1016/B978-0-444-63233-3.00009-9

9. Medina A, et al. Prevalence and Incidence of Huntington's Disease: An Updated Systematic Review and Meta-Analysis. Mov Disord. 2022;37(12):2327-2335. doi:10.1002/mds.29228

10. Oosterloo M, et al. Clinical Review of Juvenile Huntington's Disease. J Huntingtons Dis. 2024;13(2):149-162. doi:10.3233/JHD-231523

11. Anderson KE, et al. Clinical Management of Neuropsychiatric Symptoms of Huntington Disease: Expert-Based Consensus Guidelines on Agitation, Anxiety, Apathy, Psychosis and Sleep Disorders. J Huntingtons Dis. 2018;7(4):355-366. doi:10.3233/JHD-180293

12. Quinn L, et al. Clinical recommendations to guide physical therapy practice for Huntington disease. Neurology. 2020;94(5):217-228. doi:10.1212/WNL.0000000000008887

13. Loi SM, et al. Survival in Huntington's disease and other young-onset dementias. Int J Geriatr Psychiatry. 2023;38(5):e5913. doi:10.1002/gps.5913

14. Medina A, et al. Prevalence and Incidence of Huntington's Disease: An Updated Systematic Review and Meta-Analysis. Mov Disord. 2022;37(12):2327-2335. doi:10.1002/mds.29228

15. Stoyas CA, et al. The CAG-polyglutamine repeat diseases: a clinical, molecular, genetic, and pathophysiologic nosology. Handb Clin Neurol. 2018;147:143-170. doi:10.1016/B978-0-444-63233-3.00011-7

16. Loi SM, et al. Survival in Huntington's disease and other young-onset dementias. Int J Geriatr Psychiatry. 2023;38(5):e5913. doi:10.1002/gps.5913

17. Kachian ZR, et al. Suicidal ideation and behavior in Huntington's disease: Systematic review and recommendations. J Affect Disord. 2019;250:319-329. doi:10.1016/j.jad.2019.03.043

18. Rocha NP, et al. Clinical Correlates of Depression and Suicidality in Huntington Disease: An Analysis of the Enroll-HD Database. Cogn Behav Neurol. 2022;35(2):127-135. doi:10.1097/WNN.0000000000000301

19. Connors MH, et al. Apathy and Depression in Huntington's Disease: Distinct Longitudinal Trajectories. J Neuropsychiatry Clin Neurosci. 2023;35(1):72-79. doi:10.1176/appi.neuropsych.21070191

20. van Duijn E, et al. Medical treatment of behavioral manifestations of Huntington disease. Handb Clin Neurol. 2017;144:129-139. doi:10.1016/B978-0-12-801893-4.00011-0

21. Stoker TB, et al. Huntington's disease: diagnosis and management. Pract Neurol. 2022;22(1):32-41. doi:10.1136/practneurol-2021-003074

22. Heinzmann A, et al. Huntington's Disease with Small CAG Repeat Expansions. Mov Disord. 2023;38(7):1352-1357. doi:10.1002/mds.29427

23. Lee JM, et al. Genetic modifiers of Huntington disease differentially influence motor and cognitive domains. Am J Hum Genet. 2022;109(5):885-899. doi:10.1016/j.ajhg.2022.03.004

24. Caterino M, et al. Huntingtin protein: A new option for fixing the Huntington's disease countdown clock. Neuropharmacology. 2018;135:126-138. doi:10.1016/j.neuropharm.2018.03.009

25. Peng C, et al. Protein transmission in neurodegenerative disease. Nat Rev Neurol. 2020;16(4):199-212. doi:10.1038/s41582-020-0333-7

26. Smith-Dijak AI, et al. Alterations in synaptic function and plasticity in Huntington disease. J Neurochem. 2019;150(5):346-365. doi:10.1111/jnc.14723

27. Raymond LA, et al. Striatal synaptic dysfunction and altered calcium regulation in Huntington disease. Biochem Biophys Res Commun. 2017;483(4):1051-1062. doi:10.1016/j.bbrc.2016.07.058

28. Zhao DY, et al. Autophagy preferentially degrades non-fibrillar polyQ aggregates. Mol Cell. 2024;84(11):2106-2122.e8. doi:10.1016/j.molcel.2024.04.018

29. Tan B, et al. Cortical morphometry and neural dysfunction in Huntington's disease: a review. Eur J Neurol. 2021;28(6):1979-1995. doi:10.1111/ene.14648

30. Young CB, et al. Neuroanatomy, Basal Ganglia. StatPearls. 2025. (Updated 2025)

31. Stimming EF, et al. Chorea. Continuum (Minneap Minn). 2022;28(5):1333-1358. doi:10.1212/CON.0000000000001169

32. Kassavetis P, et al. Eye Movement Disorders in Movement Disorders. Mov Disord Clin Pract. 2022;9(3):271-287. doi:10.1002/mdc3.13413

33. Pizzorni N, et al. Management of dysphagia in Huntington's disease: a descriptive review. Neurol Sci. 2020;41(5):1405-1416. doi:10.1007/s10072-020-04265-0

34. Pizzorni N, et al. Oropharyngeal Dysphagia Phenotypes Across Huntington's Disease Stages: Endoscopic Findings From the SWALLOW-HD Study. J Huntingtons Dis. 2024;13(2):175-191. doi:10.3233/JHD-231519

35. Lee JM, et al. Genetic modifiers of Huntington disease differentially influence motor and cognitive domains. Am J Hum Genet. 2022;109(5):885-899. doi:10.1016/j.ajhg.2022.03.004

36. Ghosh R, et al. Clinical Features of Huntington's Disease. Adv Exp Med Biol. 2018;1049:1-28. doi:10.1007/978-3-319-71779-1_1

37. van Duijn E, et al. Medical treatment of behavioral manifestations of Huntington disease. Handb Clin Neurol. 2017;144:129-139. doi:10.1016/B978-0-12-801893-4.00011-0

38. Bakels HS, et al. Juvenile-Onset Huntington Disease Pathophysiology and Neurodevelopment: A Review. Mov Disord. 2022;37(1):87-96. doi:10.1002/mds.28823

39. Caron NS, et al. Huntington Disease. GeneReviews. 1993 (Updated 2020). PMID: 20301482

40. Quaid KA, et al. Genetic testing for Huntington disease. Handb Clin Neurol. 2017;144:113-126. doi:10.1016/B978-0-12-801893-4.00010-9

41. Nance MA, et al. Genetic counseling and testing for Huntington's disease: A historical review. Am J Med Genet B Neuropsychiatr Genet. 2017;174(1):75-92. doi:10.1002/ajmg.b.32453

42. Castro E, et al. Predictive Modeling of Huntington's Disease Unfolds Thalamic and Caudate Atrophy. Mov Disord. 2022;37(11):2358-2364. doi:10.1002/mds.29219

43. Lila E, et al. Asymmetric brain atrophy in Huntington's disease: A postmortem MRI study. J Huntingtons Dis. 2025;14(1):97-108. doi:10.1177/18796397251333334

44. Tabrizi SJ, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol. 2009;8(9):791-801. doi:10.1016/S1474-4422(09)70170-X

45. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Mov Disord. 1996;11(2):136-142. doi:10.1002/mds.870110204

46. Geschwind MD, et al. Deutetrabenazine for Treatment of Chorea in Huntington Disease. JAMA. 2016;316(1):40-50. doi:10.1001/jama.2016.8011

47. Heo YA, et al. Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease. Drugs. 2017;77(18):1987-1997. doi:10.1007/s40265-017-0831-0

48. Claassen DO, et al. Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease. J Clin Mov Disord. 2017;4:3. doi:10.1186/s40734-017-0051-5

49. Fox SH, et al. International Parkinson and movement disorder society evidence-based medicine review of treatments for the non-motor symptoms of Parkinson's disease. Mov Disord. 2018;33(5):695-717. doi:10.1002/mds.27372

50. Anderson KE, et al. Clinical Management of Neuropsychiatric Symptoms of Huntington Disease. J Huntingtons Dis. 2018;7(4):355-366. doi:10.3233/JHD-180293

51. Mendizabal A, et al. Health Services in Huntington Disease: A Systematic Literature Review. Neurol Clin Pract. 2023;13(1):e200108. doi:10.1212/CPJ.0000000000200108

52. Quinn L, et al. Clinical recommendations to guide physical therapy practice for Huntington disease. Neurology. 2020;94(5):217-228. doi:10.1212/WNL.0000000000008887

53. Pizzorni N, et al. Management of dysphagia in Huntington's disease: a descriptive review. Neurol Sci. 2020;41(5):1405-1416. doi:10.1007/s10072-020-04265-0

54. Peball M, et al. Hospital Admissions of Huntington's Disease Patients in a Huntington's Disease Centre. Mov Disord Clin Pract. 2022;9(6):757-764. doi:10.1002/mdc3.13459

55. Bonomo R, et al. Deep brain stimulation in Huntington's disease: a literature review. Neurol Sci. 2021;42(11):4407-4412. doi:10.1007/s10072-021-05527-1

56. Kaczynska J, et al. Is deep brain stimulation effective in Huntington's Disease? - a systematic literature review. Neurol Neurochir Pol. 2022;56(4):307-318. doi:10.5603/PJNNS.a2022.0050

57. Tabrizi SJ, et al. Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities. Lancet Neurol. 2022;21(7):645-658. doi:10.1016/S1474-4422(22)00121-1

58. Kwon D. Failure of genetic therapies for Huntington's devastates community. Nature. 2021;593(7858):180. doi:10.1038/d41586-021-01177-7

59. McGarry A, et al. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease. Mov Disord. 2017;32(10):1494-1498. doi:10.1002/mds.27143

60. Reilmann R, et al. Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2024;23(3):267-277. doi:10.1016/S1474-4422(23)00454-4

61. Adrissi J, et al. Electroconvulsive Therapy (ECT) for Refractory Psychiatric Symptoms in Huntington's Disease: A Case Report. J Huntingtons Dis. 2019;8(3):375-378. doi:10.3233/JHD-190361

62. Wheelock VL, et al. Predictors of nursing home placement in Huntington disease. Neurology. 2003;60(6):998-1001. doi:10.1212/01.wnl.0000052992.58107.67

63. Perez-Perez J, et al. Update on Genetic Chorea. Eur J Neurol. 2025;32(1):e70357. doi:10.1111/ene.70357

64. Piao X, et al. Advances in gene and cellular therapeutic approaches for Huntington's disease. Protein Cell. 2025;16(2):79-98. doi:10.1093/procel/pwae042

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and current guidelines.